UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE SECURITIES EXCHANGE ACT OF 1934
For the month of January 2026
Commission file number: 001-41598
LAKESHORE BIOPHARMA CO., LTD
(Exact name of registrant as specified in its charter)
Building No. 2, 38 Yongda Road
Daxing Biomedical Industry Park
Daxing District, Beijing, PRC
Tel: 010-89202086
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
EXPLANATORY NOTE
On January 21, 2026, and January 22, 2026, we
received the Arbitral Awards (the “Awards”) issued by the Kaifeng Arbitration Commission regarding three arbitration cases
involving Liaoning Yisheng Biopharma Co., Ltd. (“Liaoning Company”) and Beijing Yisheng Biotechnology Co., Ltd. (“Beijing
Company”). According to the Awards, Liaoning Company is required to pay Henan Yishengyaoye Co., Ltd. and Beijing Yisheng Xingye
Technology Co., Ltd. a total principal amount of approximately RMB446 million, and other interest and miscellaneous fees totaling more
than RMB36 million; Beijing Company is required to pay Beijing Yisheng Xingye Technology Co., Ltd. a principal amount of approximately
RMB58.5 million, and other interest and miscellaneous fees totaling approximately RMB36 million. We dispute the claims asserted by
the counterparties in the arbitrations and the validity of the arbitration results. We will vigorously challenge the Awards in all possible
means in relevant tribunals. On December 12, 2024, the Shenyang Municipal Public Security Bureau has initiated an investigation into the
relevant actions on the grounds of “Fraudulent Litigation” and is still actively pursuing the criminal case. As previously
reported, Yi Zhang, the former chairman of the Company that the Company believes had fabricated the cases, has been listed as a criminal
suspect by Chinese Public Security Authorities.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| |
LakeShore Biopharma Co., Ltd |
| |
|
| |
By: |
/s/ Rachel Yu |
| |
Name: |
Rachel Yu |
| |
Title: |
Director and Chief Financial Officer |
Date: January 29, 2026
2
